Background-Some patients with left ventricular systolic dysfunction (LVSD) have a dramatic improvement in left ventricular ejection fraction (LVEF) after β-blockade. No study has analyzed the long-term echocardiographic and clinical follow-up of this subgroup of patients. Methods and Results-We included in this analysis 174 consecutive patients with LVSD who had an LVEF≥45% after β-blockade. We performed a long-term echocardiographic follow-up (median 7.7 [4-9.9] years) and clinical follow-up (median 9.2 [7.2-10.8] years). LVEF improved from 33±8% to 54±6% after β-blockade (P<0.0001). At the last echocardiographic evaluation, 26% of the patients had an LVEF<45% (mean±SD: 34±6%), whereas 74% still had an LVEF≥45% (mean±SD: 54±6%). Independent predictors of LVEF deterioration were a low LVEF, a high left ventricular end-diastolic diameter and a low heart rate after β-blockade, and the presence of a complete left bundle-branch block. In the overall study population, survival rates were 90% at 5 years and 75% at 10 years. Cardiovascular death rate was 9%, noncardiovascular death rate was 11%, and unknown death rate was 3%. Patients with subsequent LVEF deterioration had a higher cardiovascular mortality compared with patients with sustained recovered LVEF (22% versus 4%). Conclusions-The long-term survival of patients with LVSD and with near-normal LVEF after β-blockade is good.
β -blockers are now a mandatory treatment of congestive heart failure related to left ventricular systolic dysfunction (LVSD). 1, 2 Despite their acute negative inotropic effect, β-blockers can induce a significant improvement in left ventricular ejection fraction (LVEF) in stable patients with LVSD. [3] [4] [5] The mean improvement in LVEF is close to 9% in meta-analyses, 6 and this improvement has been associated with a favorable outcome. 7, 8 In some patients, β-blockers may induce a major improvement with an almost normalization of LVEF. These patients with recovered LVEF represent a distinct subgroup of patients, different from patients with heart failure with preserved LVEF. 9 The exact mechanisms of reverse remodeling in patients with LVSD is not fully understood. 10 To the best of our knowledge, no study has analyzed the long-term clinical and echocardiographic evolution of patients with recovered LVEF after β-blockade.
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Methods
Study Population and Follow-Up
We included in this analysis all consecutive patients with stable congestive heart failure related to LVSD with an LVEF<45% referred to our department between 1998 and 2004 for introduction of β-blocker therapy and who had an LVEF≥45% after maximal tolerated doses of β-blockers with ≥5% increase in LVEF. Patients gave informed consent, and the protocol was approved by our institutional review committee.
A flow diagram of the study is shown in Figure 1 . Before the introduction of β-blockers, patients were ambulatory, clinically stable for ≥2 months, without a recent (<3 months) myocardial infarction or coronary revascularization, and all the patients received maximal tolerated doses of angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin type II receptor blockers (ARB), without any dose modifications during at least the last 2 months. The median duration between the diagnosis of LVSD and the introduction of β-blockers was 14.3 [7.9-45.9] months. In 89% of the cases, β-blocker therapy was introduced >6 months after the diagnosis of LVSD. A first echocardiogram was performed before the introduction of β-blockers. Three months after the maximal tolerated doses of β-blockers have been reached, a second echocardiogram was performed to analyze LVEF, which has to be ≥45% to include the patient in the present analysis. The median duration between the introduction of β-blockers and the second echocardiogram was 6.2 [5.26-7 .59] months. A third echocardiogram was performed 6 months after the second one to confirm LVEF improvement and thereafter patients had a standard follow-up including clinical visits and repeated echocardiographic examinations ( Figure 1 ). The median echocardiographic followup was 7.7 [4-9.9] years. The median number of echographic examinations performed during the follow-up phase was 4 [3] [4] [5] [6] per patient. The median clinical follow-up was 9.2 [7.2-10.8] years; it was performed either by direct examination or by contact with the general practitioner. All the echocardiograms were performed by experimented senior cardiologists, specialized in the management of patients with heart failure. All the echocardiographic variables were measured based on the recommendations of the American Society of Cardiology. 11 LVEDD was measured by 2-dimensional echocardiography. LVEF was measured using the biplane modified Simpson method or the 4-chamber modified Simpson method when the 2-chamber view was not adequate or by a visual estimation based on the different methods. 12
Statistical Analyses
Results are expressed as mean±SD or as median with 25th and 75th percentiles when the variable did not have a normal distribution. Qualitative variables were compared between times using McNemar test and between groups using χ 2 analysis or Fisher exact test if indicated. Comparisons of quantitative variables between 2 groups were performed either by a Student t test or by a nonparametric Mann-Whitney test as appropriate. The evolution of echocardiographic variables was compared with the general linear model for repeated measures, followed by a paired Student t test in case of significance. A compound symmetry covariance matrix was used. The percentage of patients with persistent LVEF≥45% was estimated with the Kaplan-Meier method. A multivariable logistic regression analysis and a multivariable analysis with the general linear model were performed to find independent predictors of LVEF deterioration.
Cumulative survival was estimated with the Kaplan-Meier method. Overall survival was compared with the expected survival of persons of the same age and sex in the same geographical area. Control data were obtained from the Region Nord Pas-de-Calais live tables for 2001 to 2010 provided by the French Institute of Statistics. The relative survival was computed as the ratio of the observed to expected survival. The effect of LVEF deterioration on cardiovascular death was analyzed by univariate Cox analysis with LVEF included in the model as a time-dependent variable. Heart failure death was defined as death after a hospitalization for heart failure decompensation requiring intravenous treatment or patient requiring an urgent transplantation (defined as United Network for Organ Sharing status 1). Sudden cardiac death was defined as witness unexpected death in stable patients or nonwitness unexpected death but discovered the day after. Unknown death was defined as death without any information. All events were classified blindly by 2 investigators (P.d.G., N.L.) and by 3 investigators in case of disagreement (P.d.G., N.L., M.F.). All hypotheses were 2-tailed with a 0.05 type I error rate. For 8 patients who moved out of our area, the status, alive or deceased, was known, however without recent clinical information, particularly concerning the medical treatment. Statistics were performed with the SPSS software, version 15 (Chicago, IL) and with the STATA software, version 12 (College Station, TX).
Results
Characteristics of the Study Population
We included 174 consecutive patients with LVSD who had an LVEF≥45% after β-blockade. The mean age was 52±13 years; there were 43 women (25%); most of the patients were in New York Heart Association class II (119 patients, 68%), whereas 11 patients were in class III and 44 in class I. Twelve patients were in chronic atrial fibrillation (7%); 30 (17%) had complete left bundle-branch block (LBBB); and 47 patients (27%) had ischemic cardiopathy.
The treatment of the study population is summarized in Table 1 . A total of 136 patients were receiving β-1 selective blockers, of whom 122 were on bisoprolol at a mean dose LVEF before the introduction of β-blockers was 33±8% and improved to 54±6% after β-blockade (P<0.0001). LV reverse remodeling was also documented by a decrease in LV volumes and diameter ( Table 2 ).
Echocardiographic Follow-Up
After a median duration of 7.7 [4-9.9] years, the LVEF at last echocardiographic evaluation was 48±11%. Figure 2 shows the percentage of patients for whom LVEF constantly remained ≥45%; there was a progressive time-dependent decrease in this proportion (98% at 2 years, 94% at 4 years, 90% at 6 years, and 78% at 8 years). Forty-six patients (26%) had an LVEF<45% (mean±SD: 34±6%) at the last echocardiographic evaluation, whereas 128 patients (74%) had an LVEF≥45% (mean±SD: 54±6%). As shown in Table 3 , the patients in the subgroup with subsequent LVEF deterioration differed from those of the other subgroup: they were slightly older, a complete LBBB was more frequent (30% versus 13%, P=0.006), heart rates before and after β-blockade were lower; the left ventricular end-diastolic diameter (LVEDD) after β-blockade was higher, and the LVEF after β-blockade was lower. The prescription of renin inhibitors and of β-blockers at the last follow-up was similar in patients with or without subsequent LVEF deterioration (renin inhibitors: 100% versus 94%, respectively, β-blockers: 93% versus 94%, respectively), as were the doses of different drugs (data not shown). Ten patients stopped β-blocker therapy for pulmonary reasons (n=6) or asthenia (n=4); 3 patients had a subsequent LVEF deterioration (7% of the subgroup of patients with subsequent LVEF deterioration), whereas 7 patients had a sustained LVEF improvement (6% of the subgroup of patients with sustained LVEF improvement). The type of β-blocker was not associated with the likelihood of LVEF deterioration during follow-up. Similarly, neither the delay between the diagnosis of LVSD and the introduction of β-blockers nor the delay of the titration phase of the β-blockers was associated with subsequent LVEF deterioration. Digoxin was stopped in 25 patients, 7 had a subsequent LVEF deterioration (16% of the patients of this subgroup), whereas 18 had a sustained recovered LVEF (15% of the patients of this subgroup).
By multivariable analysis, independent variables associated with a follow-up LVEF<45% were LVEF after β-blockade (hazard ratio [HR], 0.90 [0.83-0.98], P=0.02), the presence of a complete LBBB (HR, 3.52 [1.34-9.26], P=0.01), Similar results were obtained if the change in LVEF from after β-blockade to the last echocardiography was analyzed as a continuous parameter: the variables independently associated with a subsequent decrease in LVEF were a low LVEF after β-blockade (P<0.0001), the presence of a complete LBBB (P=0.05), a high LVEDD after β-blockade (P<0.0001), and a low heart rate after β-blockade (P=0.008).
Clinical Follow-Up
During a median follow-up of 9.2 [7.2-10.8] years, there were 40 deaths (23%). Figure 3 shows the Kaplan-Meier survival curve compared with expected survival. The survival rates were 90% at 5 years and 75% at 10 years. Corresponding expected survival rates were 93% at 5 years and 85% at 10 years. Relative survival was 97% at 5 years and 89% at 10 years. Table 4 shows the causes of mortality. In the overall study population, the cause of death was cardiovascular in 9%, noncardiovascular in 11%, and unknown in 3%. Patients with subsequent LVEF deterioration had a higher cardiovascular mortality compared with patients with sustained recovered LVEF (22% versus 4%). Similar results were obtained in the subgroup of patients with an LVEF≤35% before the introduction of β-blockers (Table in In patients with a complete LBBB, 14 had a subsequent LVEF deterioration, of whom 6 had an LVEF≤35%. Two patients had resynchronization therapy (of whom 1 died), whereas 4 patients died without any attempt to resynchronization therapy.
Discussion
Major improvement leading to recovery of near-normal LVEF values is not uncommon in patients receiving β-blockers for LVSD. In a study by Metra et al, 7 22% of the patients receiving β-blockers had an increase in LVEF of ≥15 absolute unit; more recently, we reported an LVEF>45% after β-blockade in 126 out of 314 patients with LVSD. 8 Although this reverse remodeling has been associated with a better midterm prognosis, its long-term implications are uncertain. Specifically, there remain questions regarding (1) the risk of subsequent LVEF deterioration and (2) the long-term clinical outcome in this particular group of patients.
To the best of our knowledge, the present report is the first demonstration of a progressive time-dependent alteration in LVEF in patients who were initially excellent responders to β-blockade. Although the majority of the patients had persistent recovery of LVEF at long term, we were able to demonstrate LVEF deterioration in approximately one quarter of our study population after 8 years of follow-up. Long-term compliance to cardiovascular drugs is an important problem and could have been an explanation for such a finding. 13 This does not however seem to be the case in our study because the rates of prescription of β-blockers (and that of other drugs) remained high at follow-up and were similar in patients with and without LVEF deterioration. Digoxin withdrawal, which has been associated with subsequent LVEF deterioration before the β-blocker era, 14 does not seem to have a significant impact in the evolution of LVEF. Withdrawal rates of digoxin were similar in patients with or without subsequent LVEF deterioration. However, in this population, any drug withdrawal (particularly β-blockers and digoxin) must be made with caution because we cannot exclude a relationship between withdrawal and a decrease in LVEF. Therefore, based on our results, a regular echocardiographic follow-up seems required to detect a decrease in LVEF, which may impact the therapeutic strategy. It must also be pointed out that some patients, particularly those with a recent diagnosis (<3 months) of dilated cardiomyopathy, could have a spontaneous LVEF improvement. 15 However, 89% of our patients received β-blocker therapy >6 months after the diagnosis of LVSD, reducing the probability of a spontaneous LVEF improvement.
Our results also suggest that some patients may be at higher risk of LVEF deterioration. Patients with lower LVEF after β-blockade and with lower heart rate appear at particular risk; however, because the differences between groups were relatively modest, the use of these parameters for risk prediction for an individual patient would be difficult. We must be particularly aware of persistent LV dilatation after β-blockade and carefully follow these patients for LVEF deterioration, which could respond to more aggressive therapy. The presence of a complete LBBB may provide an easily identifiable risk factor of subsequent decrease in LVEF. In the present study, 47% of the patients with a complete LBBB had subsequent LVEF degradation compared with only 22% in the absence of LBBB. The patients with LVEF normalization and complete LBBB therefore deserve pronounced follow-up. In case of LVEF degradation in these patients, resynchronization therapy is of course an option that should be considered. [16] [17] [18] At the inclusion in our study, none of our patients had resynchronization therapy, because LVEF was >45%. During the follow-up, 2 patients with a complete LBBB and LVEF≤35% received resynchronization therapy. The other patients with a complete LBBB either had no indication of resynchronization therapy or died before the modification of the international guidelines (concerning patients in New York Heart Association class II).
Overall, the long-term survival of our study population was good, a reassuring finding for patients and physicians in case of near-normal LVEF after β-blockade. Moreover, throughout follow-up, the cardiovascular mortality (15 patients, 9%) was lower than the noncardiovascular mortality (20 patients, 11.5%), a remarkable finding for a congestive heart failure population. There remained however an excess of mortality when compared with expected survival, and there were several cases of heart failure death or of sudden death. Our results suggest that this may be attributed to recurrent alteration in LV function. There was indeed a great consistency between clinical data and echocardiographic data. The great majority of the patients who died from cardiac causes previously had LVEF deterioration.
Several study limitations should be acknowledged. Although all consecutive patients with stable LVSD referred to our institution between 1998 and 2004 had β-blockers introduction following the protocol described in Figure 1 , the long-term echographic follow-up after the third echocardiogram was not prospective, and the patients were followed-up on a standard clinical basis. There was however a relatively high number of echocardiographic examinations per patient during the follow-up (4 [3] [4] [5] [6] ), and there was no patient lost for the long-term clinical follow-up. In addition, the number of patients included in the study was limited. However, we have a unique population in whom the impact of LVEF was mainly related to β-blocker therapy. All our patients were stable, receiving chronic maximal and stable doses of ACE-I/ ARB before the introduction of β-blockers. Currently, it is not possible to select these patients because in clinical practice ACE-I/ARB and β-blocker therapy are introduced simultaneously in naïve patients with LVSD. We used a cutoff value of 45% to differentiate patients with or without LVSD and with or without subsequent LVEF deterioration. As for all cutoff values, this level could be debated; however, in international guidelines, 1,2 the 40% to 50% threshold is used to differentiate patients with heart failure with either reduced ejection fraction or preserved ejection fraction. Finally, with the wider use of resynchronization therapy since the publication of updated international guidelines, we could not exclude a different evolution of LVEF in patients with LVSD receiving both maximal medical treatment and resynchronization therapy.
In conclusion, the long-term survival of patients with LVSD with near-normal LVEF after β-blockade is good. However, approximately a quarter of these patients may experience a subsequent degradation of LVEF. These patients are at higher risk of cardiovascular mortality.
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